AccuRna Overview

  • Year Founded
  • 2015

Year Founded

  • Status
  • Acquired/​Merged

  • Employees
  • 23

Employees

  • Latest Deal Type
  • M&A

  • Latest Deal Amount
  • $16M

AccuRna General Information

Description

Developer of drug delivery systems designed for nucleic acid therapeutics. The company offers proprietary nanotechnology platforms, including unit polyion complexes and polyplex micelles that stabilize and transport short-chain and long-chain nucleic acids, enabling pharmaceutical companies and research institutions to deliver innovative medicines for refractory diseases and cancer.

Contact Information

Website
www.accurna.com
Ownership Status
Acquired/Merged
(Operating Subsidiary)
Financing Status
Formerly VC-backed
Corporate Office
  • Sanyu Building 201, 3-42-1
  • Hongo
  • Bunkyo-ku, Tokyo
  • Japan
+81
Primary Industry
Drug Delivery
Other Industries
Drug Discovery
Biotechnology
Parent Company
Vertical(s)
Corporate Office
  • Sanyu Building 201, 3-42-1
  • Hongo
  • Bunkyo-ku, Tokyo
  • Japan
+81

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

AccuRna Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
4. Merger/Acquisition 01-Sep-2020 $16M Completed Clinical Trials - General
3. Early Stage VC 23-Dec-2019 Completed Clinical Trials - General
2. Early Stage VC 17-Jan-2018 $4.65M $5.95M Completed Startup
1. Seed Round 16-Mar-2016 $1.3M $1.3M Completed Startup
To view AccuRna’s complete valuation and funding history, request access »

AccuRna Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Class B2 preferred
Class B preferred
Class A preferred 4,900 $274.88 $274.88 1x $274.88 18.1%
To view AccuRna’s complete cap table history, request access »

AccuRna Patents

AccuRna Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
EP-3135763-A1 Method for improving protein expression, and composition for protein expression Inactive 24-Apr-2014
EP-3135763-A4 Method for improving protein expression, and composition for protein expression Inactive 24-Apr-2014
US-20170183389-A1 Method for improving protein expression, and composition for protein expression Inactive 24-Apr-2014 C07K14/65

AccuRna Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

AccuRna Former Investors (3)

Investor Name Investor Type Holding Investor Since Participating Rounds
Fast Track Initiative Venture Capital Minority
SMBC Venture Capital Corporate Venture Capital Minority
UTokyo Innovation Platform Accelerator/Incubator Minority
To view AccuRna’s complete investors history, request access »

AccuRna FAQs

  • When was AccuRna founded?

    AccuRna was founded in 2015.

  • Where is AccuRna headquartered?

    AccuRna is headquartered in Bunkyo-ku, Japan.

  • What is the size of AccuRna?

    AccuRna has 23 total employees.

  • What industry is AccuRna in?

    AccuRna’s primary industry is Drug Delivery.

  • Is AccuRna a private or public company?

    AccuRna is a Private company.

  • What is the current valuation of AccuRna?

    The current valuation of AccuRna is .

  • What is AccuRna’s current revenue?

    The current revenue for AccuRna is .

  • How much funding has AccuRna raised over time?

    AccuRna has raised $8.24M.

  • Who are AccuRna’s investors?

    Fast Track Initiative, SMBC Venture Capital, and UTokyo Innovation Platform have invested in AccuRna.

  • When was AccuRna acquired?

    AccuRna was acquired on 01-Sep-2020.

  • Who acquired AccuRna?

    AccuRna was acquired by Nano Holdings.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process